An article published in the September 2019 issue of the American Journal of Roentgenology (AJR) reveals an association between improved liver function test results and survival after transarterial embolization (TAE) for hepatocellular carcinoma (HCC) and the use of aspirin therapy.
The treatment of 304 patients was reviewed by F. Edward Boas at Memorial Sloan Kettering Cancer Center in New York City. Among 42 patients taking aspirin at the time of initial TAE for HCC, bilirubin levels were lower after the first day (0.9 vs 1.3), after 1 month (0.9 vs 1.2), and after 1 year (0.8 vs 1.0).
F. Edward Boas, Karen T. Brown, Etay Ziv, Hooman Yarmohammadi, Constantinos T. Sofocleous, Joseph P. Erinjeri, James J. Harding, Stephen B. Solomon. Aspirin Is Associated With Improved Liver Function After Embolization of Hepatocellular Carcinoma. American Journal of Roentgenology, 2019; 1 DOI: 10.2214/AJR.18.20846